© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor

PharmaVitae: Biogen Idec HC Slidepack 06/11 quality dataexpert analysisintuitive delivery the home of Business Intelligence

Biogen Idec prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

Biogen Idec financial performance ($m), 2004–16

SWOT analysis of Biogen Idec Strong licensing network Strong operating profit performance post merger Active late-stage pipeline Strong geographical presence Strengths Heavy reliance on the marketing efforts of its partner, Genentech/Roche for Rituxan Lack of broad sales and marketing experience in the oncology and inflammation markets Weaknesses BG-12 – key launch product for Biogen Idec, offering the company a road into the lucrative orally active multiple sclerosis market Highly active early to mid stage pipeline Developing more MAbs – the fastest growing market sector across the entire pharmaceutical industry Entering the hematology therapy area through the acquisition of Syntonix Opportunities Failure of BG-12 to launch Biosimilar therapeutic proteins pressure Threats

Biogen Idec enters oral MS market Biosimilar pressure Competition from Novartis’s Gilenya Sales of Biogen Idec’s leading multiple sclerosis therapies ($m),

Projected market share of the orally active multiple sclerosis therapies, (%)

Sales of Biogen Idec’s leading multiple sclerosis therapies ($m),

Biogen Idec prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

Key product sales ($m), 2004–16

Biogen Idec key product growth drivers and resistors ($m), 2004–10

Biogen Idec key product growth drivers and resistors ($m), 2010–16

Biogen Idec prescription pharmaceutical sales by therapy area ($m), 2004–16

Biogen Idec prescription pharmaceutical sales by geographic region ($m), 2004–16

Biogen Idec launch, core and expiry configuration, sales ($m), 2010–16

Biogen Idec prescription pharmaceutical sales by molecule type ($m), 2004–16

Biogen Idec prescription pharmaceutical sales by source of product ($m), 2004–16

Biogen Idec operating revenue/cost analysis ($m), 2004–16

© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor